Sugi Predict

Sugi Predict / Compounds / SCHEMBL2435935

SCHEMBL2435935

SCHEMBL2435935

Nc1ccc(CN2CCOCC2)c(C(F)(F)F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.70
▸ PDE3B Q13370 2/20 0.52
▸ PDE3A Q14432 2/20 0.52
▸ CYP2C9 P11712 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ CYP2A13 Q16696 5/20 0.47
▸ KDM4E B2RXH2 3/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ALOX5AP P20292 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ EPAS1 Q99814 1/20 0.42
▸ ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30900087 1.00 NR1H2 (0.70) NR1H2PDE3BPDE3ACYP2C9ALOX15
SCHEMBL24565655 0.95 NR1H2 (0.64) NR1H2PDE3BPDE3ACYP2C9ALOX15
SCHEMBL545052 0.86 NR1H2 (0.76) NR1H2KDM4EALDH1A1ATMGLA
SCHEMBL4933173 0.86 NR1H2 (0.76) NR1H2PDE3BPDE3AKDM4EALDH1A1
SCHEMBL3166705 0.85 NR1H2 (0.74) NR1H2KDM4EALDH1A1ATMGLA
SCHEMBL29175928 0.85 NR1H2 (0.74) NR1H2PDE3BPDE3AKDM4EMAPT
SCHEMBL29998843 0.85 NR1H2 (0.74) NR1H2KDM4EALDH1A1ATMGLA
SCHEMBL24192811 0.83 NR1H2 (0.53) NR1H2PDE3BPDE3AKDM4EALDH1A1
SCHEMBL1279087 0.82 NR1H2 (0.79) NR1H2KDM4EMAPTALDH1A1ATM
SCHEMBL10104471 0.82 PDE3B (0.55) NR1H2PDE3BPDE3ACYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US claimed
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-12-26 — — US disclosed
CN-119060018-A N, N-diaryl urea derivative and application thereof 杭州百新生物医药科技有限公司 2024-12-03 — — CN disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 — — EP disclosed
EP-4419516-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-08-28 — — EP disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-15 — — US disclosed
CN-101031560-A Cyclic diaryl ureas suitable as tyrosine kinase inhibitors NOVARTIS AG (CH) 2007-09-05 — — CN disclosed
CN-101018784-A Bicyclic amides as kinase inhibitors NOVARTIS AG (CH) 2007-08-15 — — CN disclosed
EP-1794149-A2 BICYCLIC AMIDES AS KINASE INHIBITORS Novartis AG (CH) 2007-06-13 — — EP disclosed
WO-2007031265-A2 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2007-03-22 — — WO disclosed
WO-2006118749-A1 THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-09 — — WO disclosed
US-20060241149-A1 Chemical compounds ADAMS JERRY L 2006-10-26 — — US disclosed
WO-2006059234-A2 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-06-08 — — WO disclosed
EP-1581514-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-10-05 — — EP disclosed
WO-2004043379-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425482-A1 PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 NR1H2 3245/4885PDE3B 1601/4885PDE3A 1652/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 NR1H2 2047/4885PDE3B 2077/4885PDE3A 2012/4885
US-20060241149-A1 Chemical compounds CHKB, MAP3K20, MAP3K6 NR1H2 525/4885PDE3B 959/4885PDE3A 1132/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 NR1H2 2488/4885PDE3B 3598/4885PDE3A 3845/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B NR1H2 4625/4885PDE3B 1376/4885PDE3A 2249/4885
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide ADK, MAP3K9, MAP4K5 NR1H2 1835/4885PDE3B 1718/4885PDE3A 1275/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 NR1H2 2147/4885PDE3B 1715/4885PDE3A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.